Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • ACH-4471: Interim Phase Ia data

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-4471 Business: Hematology Molecular target: Complement factor D (CFD) (adipsin) Description: Complement factor D (CFD; adipsin) inhibitor …

    Published on 6/27/2016
  • ADI-PEG 20: Phase Ib data

    Polaris Pharmaceuticals Inc., San Diego, Calif. Product: ADI-PEG 20 Business: Cancer Molecular target: NA Description: Arginine deiminase (ADI) formulated with polyethylene glycol Indication: Treat advanced pancreatic …

    Published on 6/27/2016
  • CAT-2054: Phase IIa data

    Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), Cambridge, Mass. Product: CAT-2054 Business: Endocrine/Metabolic Molecular target: Sterol regulatory element binding protein (SREBP) Description: Conjugate of niacin and …

    Published on 6/27/2016
  • Danoprevir: Interim Phase II data

    Ascletis Pharmaceuticals Co. Ltd., Shaoxing, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Danoprevir (ITMN-191, RG7227, ASC08) (formerly R7227) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 6/27/2016
  • Dextenza sustained-release dexamethasone: Phase III data

    Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Dextenza sustained-release dexamethasone (OTX-DP) Business: Inflammation Molecular target: NA Description: Hydrogel-based punctum plug that delivers …

    Published on 6/27/2016
  • Dupilumab: Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Dupilumab (REGN668, SAR231893) Business: Dermatology Molecular target: Interleukin-4 (IL-4) receptor…

    Published on 6/27/2016
  • Fluticasone furoate/umeclidinium/vilanterol: Phase III data

    Innoviva Inc. (NASDAQ:INVA), South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Fluticasone furoate/umeclidinium/vilanterol Business: Pulmonary Molecular target: Muscarinic …

    Published on 6/27/2016
  • GLPG1972: Phase I data

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium Servier, Neuilly-sur-Seine, France Product: GLPG1972 Business: Autoimmune Molecular target: NA Description: Undisclosed small molecule Indication: Treat …

    Published on 6/27/2016
  • GLPG2222: Phase I data

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: GLPG2222 Business: Pulmonary Molecular target: Cystic fibrosis transmembrane conductance regulator (CFTR) …

    Published on 6/27/2016
  • GX-188E: Interim Phase II data

    Genexine Inc. (KOSDAQ:095700), Seoul, South Korea Product: GX-188E Business: Cancer Molecular target: NA Description: Plasmid DNA therapeutic vaccine Indication: Treat cervical intraepithelial neoplasm (CIN) Endpoint: …

    Published on 6/27/2016
  • Inotuzumab ozogamicin: Phase III final data

    UCB Group (Euronext:UCB), Brussels, Belgium Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Inotuzumab ozogamicin (CMC-544, PF-5208773) Business: Cancer Molecular target: CD22 Description: Antibody-drug conjugate (ADC) …

    Published on 6/27/2016
  • IV elamipretide: Phase II data

    Stealth BioTherapeutics Inc., Newton, Mass. Product: IV elamipretide (MTP-131) (formerly Ocuvia, SS-31) Business: Endocrine/Metabolic Molecular target: NA Description: Mitochondrial-targeting tetrapeptide that binds and…

    Published on 6/27/2016
  • Keytruda pembrolizumab: Additional Phase II data

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Keytruda pembrolizumab (MK-3475) Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: Humanized IgG4 mAb against PD-1 …

    Published on 6/27/2016
  • MBX-8025: Phase II data

    CymaBay Therapeutics Inc. (NASDAQ:CBAY), Newark, Calif. Product: MBX-8025 Business: Hepatic Molecular target: Peroxisome proliferation activated receptor (PPAR) delta Description: Peroxisome proliferation activated …

    Published on 6/27/2016
  • MLR-1023: Phase IIa data

    Melior Discovery Inc., Exton, Pa. Bukwang Pharmaceutical Co. Ltd., Seoul, South Korea Product: MLR-1023 Business: Endocrine/Metabolic Molecular target: Lyn kinase (LYN) Description: Lyn kinase (LYN) activator Indication…

    Published on 6/27/2016
  • Olmutinib: Additional Phase I/II data

    Zai Lab Ltd., Shanghai, China Boehringer Ingelheim GmbH, Ingelheim, Germany Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Product: Olmutinib (HM61713, BI 1482694) Business: Cancer Molecular target: …

    Published on 6/27/2016
  • Opdivo nivolumab: Updated Phase I/II data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Opdivo nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell …

    Published on 6/27/2016
  • Pidilizumab: Preliminary Phase I/II data

    CureTech Ltd., Yavne, Israel Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Product: Pidilizumab (CT-011, MDV9300) Business: Cancer Molecular target: NA Description: Humanized mAb against an undisclosed target …

    Published on 6/27/2016
  • Poteligeo mogamulizumab: Preliminary Phase II data

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Poteligeo mogamulizumab (KW-0761, AMG 761) Business: Cancer Molecular target: CC chemokine receptor 4 (CCR4) (CD194) Description: Humanized mAb against CC …

    Published on 6/27/2016
  • Ravidasvir: Interim Phase II data

    Ascletis Pharmaceuticals Co. Ltd., Shaoxing, China Presidio Pharmaceuticals Inc., San Francisco, Calif. Product: Ravidasvir (ASC16, PPI-668) Business: Infectious Molecular target: HCV NS5A protein Description: Second-…

    Published on 6/27/2016
  • RX-3117: Phase Ib data

    Rexahn Pharmaceuticals Inc. (NYSE-M:RNN), Rockville, Md. Product: RX-3117 Business: Cancer Molecular target: DNA methyltransferase Description: Oral nucleoside analog that is activated by uridine cytidine kinase and …

    Published on 6/27/2016
  • Sitravatinib: Additional Phase I data

    Mirati Therapeutics Inc. (NASDAQ:MRTX), San Diego, Calif. Product: Sitravatinib (MGCD516) (formerly MG516) Business: Cancer Molecular target: Ret proto-oncogene (RET) Description: Small molecule inhibitor of tyrosine …

    Published on 6/27/2016
  • Tecentriq atezolizumab: Additional Phase Ib data

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Tecentriq atezolizumab (Anti-PDL1) (MPDL3280A, RG7446) Business: Cancer Molecular target: Programmed cell death 1 …

    Published on 6/27/2016
  • ToleroMune cat allergy therapy: Phase III data

    Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. Product: ToleroMune cat allergy therapy, Cat-PAD, Cat-SPIRE Business: Inflammation Molecular target: NA Description: T cell vaccine using ToleroMune T cell epitope …

    Published on 6/27/2016
  • VXM01: Phase I data

    Vaximm AG, Basel, Switzerland Product: VXM01 Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) Description: Oral T cell vaccine targeting VEGF receptor 2 (…

    Published on 6/27/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993